• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, July 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

MMV and DNDi make compounds available for research into new drugs for pandemic diseases

Bioengineer by Bioengineer
January 29, 2019
in Health
Reading Time: 5 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Pandemic Response Box harnesses open and collaborative approaches to medical innovation

Geneva – 29 January 2019 – Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases.

The Pandemic Response Box is a collection of structurally diverse antibacterial, antiviral and antifungal compounds – selected by disease experts – for screening against infectious and neglected diseases. The compounds are in various phases of drug discovery or development. In return for receiving the drug-like molecules free of charge, researchers from around the world agree to make their screening results publicly available and to publish their findings in an open access journal two years following data generation.

Since the beginning of 21st century, the world has battled multiple epidemics, old and new, caused by viruses and bacteria. Some of these epidemics have reached pandemic proportions. For example, the Zika virus outbreak in 2015-2016 in the Americas demonstrated how a relatively obscure mosquito-borne disease can become a global health emergency.

“The Pandemic Response Box came about in response to the need to be prepared for a future global health emergency,” said Dr Timothy Wells, Chief Scientific Officer, MMV. “Open innovation is one of the keys to unlocking new potential for drug discovery and tapping into existing expertise to kickstart new research efforts. The hope is that these efforts will contribute to the discovery and development of next generation therapies to manage a future pandemic as well as existing threats such as the Zika virus and Ebola.”

The emergence and spread of drug-resistant pathogens has further increased the frequency and gravity of these epidemics, posing a major threat to the world’s population. For instance, experts estimate the number of deaths associated with antimicrobial drug resistance will increase to 10 million a year by 2050.

“A deeper understanding of disease pathogenesis, as well as research into new, effective therapies could prevent the scenario of drug-resistant pathogens emerging and spreading,” said Dr Graeme Bilbe, Research & Development Director at DNDi. “The goal is to help shorten the time between the emergence of a new pandemic and the availability of new drugs to treat it. History has repeatedly shown that saving time, saves lives.”

The Pandemic Response Box is one of several MMV and DNDi open science projects, which encourage collaboration and transparency in drug development research. MMV and DNDi can provide advice, support and additional compound quantities to help researchers follow up on interesting findings.

###

https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf

More details on the box and how to order it can be found on the Pandemic Response Box https://www.mmv.org/mmv-open/pandemic-response-box webpage.

About MMV

Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

Since its foundation in 1999, MMV and partners have built the largest portfolio of antimalarial R&D and access projects ever assembled, have brought forward nine new medicines and have assumed the access stewardship of a further two. An estimated 1.9 million lives have been saved by these MMV co-developed medicines. MMV’s success is based on its extensive partnership network of around 150 active partners including from the pharmaceutical industry, academia and endemic-countries.

MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.

MMV Open: Open innovation is taking drug discovery to the next level. MMV is proud to lead several open initiatives in drug discovery for malaria and neglected diseases. The data, findings and results emanating from these initiatives are as rich as the connections and collaborations they have inspired.

  • The Pathogen Box https://www.mmv.org/mmv-open/pathogen-box contains 400 diverse, drug-like molecules active against neglected diseases.
  • The Malaria Box https://www.mmv.org/mmv-open/malaria-box was a treasure trove of 400 diverse compounds with antimalarial activity made available free of charge until December 2015.
  • Open Source Drug Discovery programme https://www.mmv.org/mmv-open/open-source-drug-discovery-programme aims to share all information, data and ideas in real time and openly with fellow researchers.

MMV enquiries:

Jaya Banerji +41 79 707 7181 [email protected] (Geneva)

Elizabeth Poll +4179 907 5992 [email protected] (Geneva)

About DNDi

A not-for-profit research and development organization, DNDi is dedicated to fostering innovation and advancement in global health by supporting the neglected diseases research community to develop safe, effective, and affordable new treatments for neglected patients. Since its inception in 2003, DNDi has delivered eight new treatments, including its first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.

DNDi‘s open innovation work includes:

  • The NTD Drug Discovery Booster https://www.dndi.org/diseases-projects/open-innovation/drug-discovery-booster/, which brings together eight pharmaceutical companies, and aims to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease;
  • The Open Synthesis Network https://www.dndi.org/diseases-projects/open-innovation/open-synthesis-network/ – a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases;
  • The Mycetoma Open Source project https://www.dndi.org/diseases-projects/open-innovation/mycetos/, which aims to discover new treatments for fungal mycetoma;
  • Guides to free computational chemistry tools. https://www.dndi.org/diseases-projects/open-innovation/guides-computational-chemistry-tools/ for drug discovery

Media contact

  • DNDi Geneva: Moyette Gibbons, [email protected], + 41 22 555 1929

MMV Disclaimer

This document contains certain forward-looking statements that may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions, or by discussion of, among other things, vision, strategy, goals, plans, or intentions. It contains hypothetical future product target profiles, development timelines and approval/launch dates, positioning statements, claims and actions for which the relevant data may still have to be established. Stated or implied strategies and action items may be implemented only upon receipt of approvals including, but not limited to, local institutional review board approvals, local regulatory approvals, and following local laws and regulations. Thus, actual results, performances or events may differ from those expressed or implied by such statements.

We ask you not to rely unduly on these statements. Such forward-looking statements reflect the current views of Medicines for Malaria Venture (MMV) and its partner(s) regarding future events, and involve known and unknown risks and uncertainties.

MMV accepts no liability for the information presented here, nor for the consequences of any actions taken on the basis of this information. Furthermore, MMV accepts no liability for the decisions made by its pharmaceutical partner(s), the impact of any of their decisions, their earnings and their financial status.

Media Contact
Moyette Gibbons
[email protected]
https://www.dndi.org/2019/media-centre/press-releases/mmv-dndi-400-compounds-available-stimulate-research-new-drugs-pandemic-diseases

Tags: DiagnosticsDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesIntellectual PropertyMedicine/HealthPharmaceutical SciencePharmaceutical SciencesPublic HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

How the MISSION Act is Transforming Quality and Outcomes of Major Cardiovascular Procedures in Veterans

July 31, 2025
blank

Mouse Lemur Cell Atlas Unlocks Primate Insights

July 31, 2025

Profiling Antibodies Targeting Chemical Modifications in Antisense Oligonucleotides

July 31, 2025

Multiomics Uncovers Key Heart Failure Targets

July 31, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Scientists Uncover Why Optimal Transport Theory Excels in Generative Models

How the MISSION Act is Transforming Quality and Outcomes of Major Cardiovascular Procedures in Veterans

Leopard Seals Sing: Under-Ice Sounds Flow Like Nursery Rhymes

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.